NVAX Sep 2024 2.500 call
| Previous Close | 2.1700 |
| Open | 2.1700 |
| Bid | 2.0500 |
| Ask | 2.5600 |
| Strike | 2.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 2.1700 - 2.1700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 210 |
- Yahoo Finance Video
Sanofi vaccine deal kicks off Novavax's 'new chapter': Analyst
Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B. Riley Securities Managing Director & Group Head of Healthcare Research Mayank Mamtani joins Market Domination to break down the deal. The co-exclusive licensing agreement between the two pharmaceutical companies includes co-commercializing Novavax's COVID-19 vaccine and developing a combination vaccine for the flu and COVID-19. Mamtani highlights that the perception of Sanofi as rescuing Novavax during a post-pandemic struggle is "absolutely true, and it makes the company and the stock investable." He adds that the deal will mark a "new chapter" for Novavax. However, he warns of some of the realities the two companies will have to overcome to be successful. "In the past couple of years, we have completely misread how the vaccination uptake rates would look like," the analyst explains. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
- Yahoo Finance Video
Novavax-Sanofi vaccine deal, Yelp and Sweetgreen earnings: Morning Brief
On today's episode of The Morning Brief, Hosts Seana Smith and Brad Smith break down some of the biggest news affecting the market (^DJI, ^IXIC, ^GSPC). President Biden is reportedly set to release a new wave of tariffs targeting China in critical sectors, including electric vehicles, semiconductors, and solar equipment. Novavax (NVAX) shares skyrocket following the announcement of a $1.2 billion deal with Sanofi (SNY) to commercialize its combined COVID-19 and flu shot. Restaurant and business review platform Yelp (YELP) misses first-quarter earnings estimates as US consumer spending remains relatively weak. Taiwan Semiconductor (TSM) sales jumped nearly 60% year-over-year as the artificial intelligence race heats up and demand for chips rises. Wedbush Securities Managing Director Dan Ives joins Yahoo Finance to discuss "the fourth Industrial Revolution" in AI and Apple's (AAPL) position among other Big Tech competitors. Sweetgreen (SG) shares soar after topping first-quarter revenue expectations and raising its full-year guidance. CEO Jonathan Neman joins to discuss the company's plans moving forward. This post was written by Melanie Riehl
BloombergNovavax’s 99% Surge Gives ‘Rib-Crunching’ Squeeze to Shorts
(Bloomberg) -- Novavax Inc.’s record one-day gain is forcing some short sellers betting against the stock to exit their positions at a loss. Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedBiden Set to Hit China EVs, Strategic Sectors With TariffsAckman Scolded Over DEI Views at Closed-Door Milken SessionJim Simons, Code Breaker Who Mastered Investing, Dies at 86Apple Apologizes for iPad Pro Ad, Scraps Plan to Air It on TVShares of the vaccine maker soare
